Rx Price Clusters Parallel Managed Care Premiums, AstraZeneca Exec Says
Executive Summary
Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.
You may also be interested in...
Merck Says R&D Efficiency Is Above Average, Rx Prices Not Tied To Research
The increasing cost of drug development will force companies to compete based on the efficiency of their R&D programs, Merck CEO Raymond Gilmartin suggested during a Nov. 30 Tufts Center for the Study of Drug Development briefing in Philadelphia
Merck Says R&D Efficiency Is Above Average, Rx Prices Not Tied To Research
The increasing cost of drug development will force companies to compete based on the efficiency of their R&D programs, Merck CEO Raymond Gilmartin suggested during a Nov. 30 Tufts Center for the Study of Drug Development briefing in Philadelphia
Medicare Rx Cost Controls Could Drive "Breakthrough" R&D - Rep. Stark
Medicare prescription drug budgets should be designed to encourage research into "truly new products," Rep. Stark (D-Calif.) suggested in an Aug. 8 memorandum submitted to the HHS drug pricing conference in Washington, D.C.